Search the Newsreel

Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision

Inovio Pharmaceuticals Inc. (INO) stock surged by 19.99% following a Jefferies upgrade to Buy, betting on a positive FDA decision for its INO-3107 treatment for recurrent respiratory papillomatosis. The company's Q2 loss per share improved significantly, and management believes current cash reserves can fund …

Analysts Have Lowered Expectations For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Its Latest Results

94,594 Shares in Air Products and Chemicals, Inc. $APD Purchased by S&CO Inc.

S&CO Inc. has acquired 94,594 shares of Air Products and Chemicals (NYSE:APD) for approximately $27.7 million, making it their 17th largest holding. The company recently reported strong quarterly earnings, beating analyst estimates with an EPS of $3.47 and a 4.6% year-over-year revenue increase. Analysts …

S&CO Inc. Acquires New Holdings in Intuitive Surgical, Inc. $ISRG

S&CO Inc. has acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by purchasing 5,121 shares valued at approximately $2.04 million in the second quarter. This move comes as Intuitive Surgical reported strong quarterly results, exceeding analyst estimates with earnings of $2.80 per share …

SCS Capital Management LLC Invests $34.78 Million in Alnylam Pharmaceuticals, Inc. $ALNY

SCS Capital Management LLC has invested $34.78 million in Alnylam Pharmaceuticals, acquiring 115,549 shares, which represents about 0.09% of the company. Institutional investors now own 92.97% of Alnylam's stock, while analysts maintain a "Moderate Buy" rating with an average price target of $393.86, despite …

What Westlake (WLK)'s Return To Profitability And Ongoing Dividend Growth Means For Shareholders

Westlake Corporation reported a return to profitability in Q2 2026 with sales of US$3,271 million and net income of US$260 million, a significant improvement from a net loss in the prior year. This, coupled with 22 years of dividend increases, suggests a strong commitment …

DLocal (DLO) Lifted Its Guidance, Is The Stock Still Undervalued?

Die Barry-Callebaut-Aktie bleibt im Fokus von Umsatzwachstum und Margendruck

2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming

The State of Wyoming recently acquired 2,410 shares of Madrigal Pharmaceuticals (MDGL) worth approximately $1.29 million, with institutions collectively owning 98.5% of the company. Madrigal Pharmaceuticals reported stronger-than-expected quarterly results, and analysts maintain a "Moderate Buy" rating despite recent insider share sales.

48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming

The State of Wyoming recently purchased 48,794 shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) valued at approximately $1.23 million during the second quarter. This move is part of broader institutional investment, as such entities now own 96.71% of the company's stock. Analysts maintain a "Moderate Buy" …

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

S&CO Inc. Buys Shares of 4,103 Vertex Pharmaceuticals Incorporated $VRTX

S&CO Inc. recently acquired 4,103 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) worth approximately $2.04 million during the second quarter. This purchase contributes to institutional investors collectively owning 90.96% of Vertex's outstanding stock. Despite missing earnings per share estimates slightly, Vertex reported strong revenue growth and …

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Alnylam Pharmaceuticals has experienced a significant stock sell-off due to lowered revenue guidance for its ATTR products and competition from BridgeBio. However, the article argues that the market reaction is overdone, highlighting Amvuttra's strong sales growth, a favorable competitive landscape after a rival drug's …

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

Enterprise value to EBIT forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX

This article provides financial data for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to EBIT forward ratio. The content appears to be a snapshot from a financial data platform, indicating market status and offering various tools and resources.

Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA

Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Mobia Medical, Inc. (NASDAQ:MOBI) Given Average Recommendation of "Moderate Buy" by Analysts

Number of shareholders of Twareat Medical Care Co. – TADAWUL:9627

ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Moderate Buy" by Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received a "Moderate Buy" consensus rating from nine analysts, with an average 12-month price target of $192.80. The company recently surpassed quarterly earnings and revenue expectations, reporting $2.37 EPS on $547.88 million in revenue, and provided fiscal 2026 EPS …

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ionis Pharmaceuticals, Inc., providing detailed financial metrics for each fund. The ETFs are sorted by market value and include information such as weight of Ionis stock, issuer, management style, expense ratio, assets …

Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS

Empowered Funds LLC significantly increased its stake in Ionis Pharmaceuticals, Inc. during the first quarter, now holding over 103,000 shares valued at $7.75 million. Institutional investors collectively own 93.86% of the company, while insiders have sold a substantial amount of shares. Despite recent price …

Empowered Funds LLC Buys 16,525 Shares of Alpha Metallurgical Resources, Inc. $AMR

Empowered Funds LLC increased its stake in Alpha Metallurgical Resources, Inc. (NYSE:AMR) by 79.4% in the first quarter, adding 16,525 shares and bringing its total holdings to 37,347 shares valued at approximately $7.7 million. Other institutional investors also adjusted their positions in AMR, which …

Bank Hapoalim BM Invests $2.67 Million in Zscaler, Inc. $ZS

Bank Hapoalim BM recently acquired 18,885 shares of Zscaler, Inc. (NASDAQ:ZS) worth approximately $2.67 million during the second quarter. This investment is part of broader institutional interest, with several other large investors also increasing their stakes in the cloud security company. Despite recent analyst …

Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD

Assenagon Asset Management S.A. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by selling 57,075 shares, decreasing its holdings by 73.1%. Despite this, other institutional investors have either increased their positions or acquired new ones in ACADIA Pharmaceuticals. Insider selling also occurred, with executives …

125,970 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 125,970 shares valued at approximately $62.52 million during the second quarter. Other hedge funds have also adjusted their holdings in the company, which is 90.96% owned by institutional investors. Vertex …

Inspire Medical Systems (INSP) Stock May Be Cheap After A 74% Fall

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Inspire Medical Systems stock has had a difficult run over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples …

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Zscaler, Inc. (NASDAQ:ZS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Zscaler, Inc. (NASDAQ:ZS) has received a consensus "Moderate Buy" rating from analysts, with 34 out of 41 firms recommending to buy the stock. The average 12-month price target is set at $214.21, following recent quarterly results that surpassed expectations, reporting adjusted EPS of $1.08 …

Helical Tightens Capital Structure with Treasury Share Buyback

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …